IP Library Granted Patent US 10,543,210
Granted Patent B2
US 10,543,210 · App. 16/366,674 · Granted Jan 28, 2020

Inhibitors of multidrug resistance transporter P-glycoprotein

Inventors: John G. Wise (Dallas, TX); Pia D. Vogel (Dallas, TX); Alexander R. Lippert (Dallas, TX); Amila K. Nanyakkara (Dallas, TX); Maha A. Aljowni (Dallas, TX)
Assignee: Southern Methodist University
A61K31/5025A61K31/353A61K31/4196A61K31/4525A61P35/00A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,543,210
App. No.
16/366,674
Granted
Jan 28, 2020
Kind
B2
Abstract

The present disclosure provides a method of treating a subject that is resistant to one or more drugs by identifying a subject having one or more drug resistant cells; administering to the subject a pharmaceutically effective amount of an inhibitor compound, and contacting one or more drug resistant cells with the inhibitor compound to reduce the export of the inhibitor compound from the one or more drug resistant tumor cells and to block the transport of drug(s) from the one or more drug resistant cells.

Claims (6)

1. A method of sensitization and re-sensitization of a prostate or liver cancer cells to a chemotherapeutic comprising the steps of:

identifying a subject having one or more cancer cells that express P-glycoprotein in need of sensitization and re-sensitization to one or more chemotherapeutic;

administering to the subject a pharmaceutically effective amount of an inhibitor compound having one of the following structural formulas:

2. The method of claim 1 , wherein the inhibitor compound interacts with one or more ATP binding domain(s) of a P-glycoprotein, or does not bind to drug binding sites on the P-glycoprotein.

3. The method of claim 1 , wherein the prostate or liver cancer cells are multidrug resistant cancer cells or tumor cells or cancer stem cells.

4. The method of claim 1 , further comprising the step of administering one or more chemotherapeutic agents to the subject.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 27, 2019
From: WISE, JOHN G.; VOGEL, PIA G.; LIPPERT, ALEXANDER R.; NANYAKKARA, AMILA K.; ALJOWNI, MAHA A.
To: SOUTHERN METHODIST UNIVERSITY
Reel/Frame 048718/0232 →
Continuity (5)
Continuation 15911441 · Mar 5, 2018
Continuation In Part 15406036 · Jan 13, 2017
Continuation 14598022 · Jan 15, 2015
Provisional Application 61927767 · Jan 15, 2014
Related Publication 20190216811A1 · Jul 18, 2019